July 22, 2023

The Eu­ro­pean Med­i­cines Agency’s hu­man med­i­cines com­mit­tee (CHMP) rec­om­mend­ed against con­di­tion­al au­tho­riza­tion for Mi­rati’s KRAS G12C in­hibitor Kraza­ti in non-small cell lung can­cer this week,

Pfiz­er said Fri­day it is as­sess­ing the se­vere­ly dam­aged plant in North Car­oli­na and mov­ing fin­ished med­ica­tions to near­by sites amid on­go­ing con­cern that short­ages

Up-and-com­ing brands from Ab­b­Vie, Bris­tol My­ers Squibb and Eli Lil­ly got a lot of net­work TV air­time in the first half of 2023. Com­mer­cials for

Roche pulled its mar­ket­ing au­tho­riza­tion ap­pli­ca­tion with the Eu­ro­pean Med­i­cines Agency (EMA) ear­li­er this month to ex­pand the la­bel for its can­cer med­i­cine Gazy­varo, be­cause

Emer­gent BioSo­lu­tions said its an­thrax vac­cine re­ceived full FDA ap­proval, though the com­pa­ny has pro­vid­ed dos­es of the vac­cine to the US gov­ern­ment for al­most

Con­tract man­u­fac­tur­er Lon­za tem­pered its sales out­look for the rest of the year due in part to low­er-than-ex­pect­ed growth in the ser­vices it pro­vides to